Roche (OTCMKTS:RHHBY – Get Rating) had its price objective cut by JPMorgan Chase & Co. from CHF 390 to CHF 370 in a report released on Friday morning, The Fly reports. They currently have a neutral rating on the stock.
Several other research firms have also commented on RHHBY. Stifel Nicolaus assumed coverage on Roche in a research note on Monday, February 28th. They set a buy rating for the company. Citigroup started coverage on shares of Roche in a research note on Wednesday, December 22nd. They set a buy rating for the company. Finally, Zacks Investment Research upgraded shares of Roche from a hold rating to a strong-buy rating and set a $58.00 target price for the company in a research note on Wednesday, January 19th. Five research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of Buy and a consensus target price of $158.14.
Shares of RHHBY stock opened at $46.42 on Friday. The business has a 50-day simple moving average of $48.10 and a 200-day simple moving average of $48.68. The company has a debt-to-equity ratio of 0.57, a current ratio of 0.93 and a quick ratio of 0.73. Roche has a 52-week low of $39.99 and a 52-week high of $52.47.
Several hedge funds have recently bought and sold shares of RHHBY. First Horizon Advisors Inc. lifted its position in shares of Roche by 76.4% during the 4th quarter. First Horizon Advisors Inc. now owns 709 shares of the company’s stock valued at $35,000 after acquiring an additional 307 shares during the period. Vigilant Capital Management LLC increased its stake in shares of Roche by 94.4% during the 3rd quarter. Vigilant Capital Management LLC now owns 972 shares of the company’s stock worth $44,000 after purchasing an additional 472 shares in the last quarter. IFP Advisors Inc increased its stake in shares of Roche by 42.0% during the 3rd quarter. IFP Advisors Inc now owns 2,787 shares of the company’s stock worth $128,000 after purchasing an additional 824 shares in the last quarter. Elmwood Wealth Management Inc. purchased a new stake in Roche in the 4th quarter worth approximately $128,000. Finally, Roanoke Asset Management Corp NY purchased a new stake in Roche in the 4th quarter worth approximately $207,000. Institutional investors own 0.18% of the company’s stock.
About Roche (Get Rating)
Roche Holding AG operates as a research healthcare company. It operates through the following divisions: Pharmaceuticals and Diagnostics. The Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized & point of care solutions, molecular diagnostics, tissue diagnostics & diabetes care.
Recommended Stories
Want More Great Investing Ideas?
Receive News & Ratings for Roche Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Roche and related companies with MarketBeat.com’s FREE daily email newsletter.
